Rosalind Research Observatory

Cycle 8 · 2026-10-02

AI Biomedical Convergence Tracker — Cycle 8

New deal, scientific-agent, sovereign and clinical signals thickened the convergence substrate without closing any capture-event gate.

Boundary: Independent public-source observatory. Not affiliated with OpenAI, Novo Nordisk, Rosalind Biodefense, GPT-Rosalind, Huawei, or any access program. No medical advice, biological protocols, laboratory guidance, access brokerage, or operational enablement is provided.
0Elevated
6Alert
0/11Chinese-primary
35Held for primary

Capture-event state

P1: not_crossed P2: not_crossed P3: not_crossed P4: partial

Source integrity

Immutable report source

Published from the Cowork Scout report with SHA-256 7d360f89703a2ce9f23f9bccc77460aff50ee8ed5033d7ee5f4232d57f719baf. The complete Markdown is also available as report.md.

Primary anchors

AI Biomedical Convergence Tracker — Cycle 8 (2026-10-02)

Window: 2026-09-29 00:00 UTC → 2026-10-02 12:00 UTC (~3 days). Clusters touched: 1, 3, 5 (in-window) + 1, 3, 5 gap-fills (pre-seed baseline misses). Capture-event parts at close: P1 not_crossed / P2 not_crossed / P3 not_crossed / P4 partial (unchanged).

SIGNALS (in-window)

[CLUSTER 3 — BIG-PHARMA AI ADOPTION]

Signal: Profluent and BioMarin announced strategic collaboration to design novel medicines using AI, pairing Profluent's generative AI protein design models with BioMarin's enzyme replacement therapy expertise for genetically defined conditions (2026-09-30). Primary URL: https://www.profluent.bio/media/profluent-partners-with-biomarin-to-design-novel-medicines-using-ai Confirmation tier: OFFICIAL Type: pharma-deal Consequence class: deal-market-repricing + capability-shift (generative-AI protein design entering a big-pharma rare-disease / enzyme-replacement vertical for the first time at this scope) Contradicts_baseline: false Convergence_tag: AI_drug_reaches_patient (upstream — discovery) Why it matters: BioMarin is the dedicated big-pharma leader in enzyme replacement therapies (Aldurazyme, Naglazyme, Vimizim, Brineura, Palynziq, Voxzogo). Profluent is the AI protein design shop that signed the $2.25B Lilly deal (2026-04-28) for AI-designed gene editors. This is the second big-pharma deal in Profluent's history and the first time generative AI protein design is explicitly paired with the enzyme replacement therapy (ERT) modality in a big-pharma collaboration. Clears AI-designed gate per primary ("Profluent's AI models"). Deal structure not disclosed in primary — HELD for financial-terms byte-check if a subsequent SEC filing surfaces. Cluster 3 baseline gains a BioMarin AI-native line distinct from the Lilly, Novo, Novartis, Genentech, BMS lineage. Urgency: Alert Cross-tie: Cluster 6 (generative AI protein design, adjacent to open-source RFdiffusion/Baker lineage but Profluent's models are proprietary — do NOT fuse). Frame-contest-tracker: NOT flagged (clears hook #7 gate).

[CLUSTER 3 — BIG-PHARMA AI ADOPTION]

Signal: Rakovina Therapeutics (TSXV: RKV) partnered with Boston-based Celvion Therapeutics to leverage AI and real-world clinical data for precision cancer drug development (2026-10-01). Primary URL: https://www.biospace.com/collaboration (listing); Rakovina press page shows Oct 1 entry — primary URL to be byte-checked next cycle once press release page URL is resolvable (rakovinatherapeutics.com/news-and-events/ 404'd on this fetch, press title confirmed on Rakovina news listing) Confirmation tier: OFFICIAL (via Rakovina news listing + biospace collaboration index) Type: pharma-deal (small-cap AI biotech × AI biotech, NOT big-pharma counterparty) Consequence class: pipeline-progression (precision oncology; CELvion contribution is RWD, Rakovina's is AI drug design) Contradicts_baseline: false Convergence_tag: AI_drug_reaches_patient (upstream — discovery) Why it matters: Rakovina is a small-cap AI oncology biotech; Celvion is private and not a big-pharma. This deal does NOT satisfy Cluster 3 "big-pharma platform deal" criterion. Documented here for pattern tracking only — AI biotechs are increasingly contracting with each other (RWD × AI design pairing) rather than exclusively with big-pharma. Does NOT contribute to P3 capture-event test. Watch for whether this pattern becomes recurring (hits #2, #3 would mean an inter-AI-biotech sub-market is forming). Urgency: Routine (documentation only) Cross-tie: none this cycle.

COUNTER-TREND / FRAME-DRIFT SILENCE CATCHES (in-window)

[CLUSTER 3 — non-AI deal, aggregator-flattening risk]

Signal: Regeneron and Sanofi expanded their global alliance with multiple next-generation, long-acting immunology antibodies (2026-10-01). Primary URL: https://www.biospace.com/collaboration (listing; Sanofi/Regeneron investor pages for byte-check next cycle) Confirmation tier: OFFICIAL (listing); primary deal-terms to be byte-checked Type: pharma-deal (NON-AI per available primary language — "next-generation, long-acting immunology antibodies" without AI methodology mention) Contradicts_baseline: false Convergence_tag: none Why it matters: Sanofi + Regeneron are a long-standing partnership (Dupixent lineage). This expansion is NOT tagged with AI design per the available headline. Do NOT admit to Cluster 3 AI-baseline. Flag for frame-contest-tracker if any aggregator in next 7 days bundles it as "AI drug discovery deal". Byte-check Sanofi + Regeneron investor pages next cycle to confirm no AI methodology is named in the primary. Urgency: Routine (documentation only) Cross-tie: frame-contest-tracker (watch).

[CLUSTER 3 — non-AI deal, aggregator-flattening risk]

Signal: Ro and Novo Nordisk announced research collaboration to generate first-of-its-kind real-world evidence on the Wegovy pill (2026-09-30). Primary URL: https://www.biospace.com/collaboration (listing) Confirmation tier: OFFICIAL (listing) Type: pharma-deal (RWE collaboration, not AI drug discovery) Contradicts_baseline: false Convergence_tag: none Why it matters: Real-world evidence partnership on oral semaglutide. NOT a drug-discovery AI deal. Documented so this is NOT silently promoted into Cluster 3 AI-baseline by aggregators conflating "AI/data" partnerships with "AI drug discovery" partnerships. Urgency: Routine (documentation only) Cross-tie: none.

BASELINE GAPS SURFACED THIS CYCLE (pre-seed; recommend terminal-Scout fold into baseline)

[CLUSTER 1 — FRONTIER AI SCIENTIFIC MOVES] — pre-seed baseline gap

Signal: Anthropic launched Claude Opus 5.5 with expanded biology capabilities, including a long-horizon molecular prediction and design evaluation conducted in collaboration with Dyno Therapeutics (2026-09-23). Primary URL: https://www.mobihealthnews.com/news/anthropic-launches-claude-opus-55-expanded-biology-capabilities (official-tier republish; anthropic.com/news/claude-opus-5-5 is the canonical primary but returned 404 on this fetch — HELD for byte-check next cycle) Confirmation tier: OFFICIAL (via mobihealthnews reporting of Anthropic release); PENDING anthropic.com direct byte-check Type: frontier-agent-release + scientific-workbench Consequence class: capability-shift Contradicts_baseline: false Convergence_tag: closed_loop_lab (indirect — a stronger biology-tier frontier model under the Life Sciences Verification Program is upstream of agent-driven wet-lab primitives) Why it matters: Direct scientific-workbench strengthening for Cluster 1. The Dyno Therapeutics collaboration is a NAMED pharma partner for molecular-prediction benchmarking — a new pattern beyond the Benchling / Allen Institute / HHMI / Coefficient Bio / Basecamp lineage. "Scientific novelty rated comparable to the strongest model previously evaluated" is the frame expert red-teamers used. 40% lower cost + 30% faster output. State stamp holds SCIENTIFIC_AGENT_LAYER_STRENGTHENING — this is confirmatory evidence, not a stamp-advance. MISSED in Cycles 6 and 7 — Cycle 6 (2026-09-25) and Cycle 7 (2026-09-29) both ran after this release and did not catch it. Flag for terminal baseline fold. Urgency: Alert Cross-tie: model-intelligence-tracker (Opus 5.5 is a general-capability release, pharma dimension cross-ties here).

[CLUSTER 1 — FRONTIER AI SCIENTIFIC MOVES] — pre-seed baseline gap

Signal: Anthropic launched the Life Sciences Verification Program (LSVP) in beta — a verified-access program granting pharma companies, academic labs, and biotech startups access to Claude Opus 5.5, Mythos 5.1, Opus 5, and Sonnet 5 with refined biology safeguards; applicants undergo review of research credentials, security standards, and ethical oversight (2026-09-17 per mobihealthnews reporting; "program launched earlier in September 2026" per mobihealthnews). Primary URL: https://support.claude.com/en/articles/16975617 (program documentation primary); https://claude.com/form/life-sciences-verification-program (application form primary) Confirmation tier: OFFICIAL Type: scientific-workbench + enterprise-deployment Consequence class: infrastructure-availability (sovereign-adjacent — gated access to frontier biology model layer by verified identity) Contradicts_baseline: false Convergence_tag: none (standalone infrastructure primitive) Why it matters: First formal verified-access program by a frontier AI lab for life-sciences organizations. Explicit biology safeguards + credential verification + ethical review as access gate — mirrors the pattern of regulated-industry verification programs. Available via Enterprise, Team, API only; Pro, Max, and cloud-provider access excluded. Up to 100 seats per approved team. Optional High-risk Use add-on for virology / toxin research. NOT PHI during beta. Significance: creates a two-tier Claude access regime where verified life-sciences organizations get a different safety-shaped model surface than general users. MISSED in Cycles 4, 5, 6, 7. Flag for terminal baseline fold under Cluster 1 scientific-workbench line. Urgency: Alert Cross-tie: sovereign-events-scout (verified-identity gating of frontier model access by sector is sovereign-adjacent infrastructure).

[CLUSTER 5 — SOVEREIGN AI-PHARMA] — pre-seed baseline gap

Signal: FDA issued Federal Register notice (2026-04-29, Docket No. FDA-2026-N-4390) announcing "AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program" — a voluntary pilot inviting drug development sponsors to apply across CDER, CBER, or the Oncology Center of Excellence; scope includes AI-enabled patient recruitment optimization, dose escalation, safety monitoring, adaptive trial design, Phase-1-to-Phase-2 decision acceleration, and biomarker assessment, under NIST AI Risk Management Framework (comment deadline 2026-05-29). Primary URL: https://public-inspection.federalregister.gov/2026-08281.pdf (primary); https://policyrisk.com/federal-register/2026-08281 (summary) Confirmation tier: OFFICIAL Type: regulatory Consequence class: regulatory-frame-shift Contradicts_baseline: false Convergence_tag: sovereign_ai_pharma Why it matters: First US FDA pilot program EXPLICITLY addressing AI in clinical trial design and execution. Although it targets trial OPTIMIZATION (not AI-DESIGNED drug approval), the pilot establishes a formal regulatory sandbox for AI-generated evidence in drug submissions — a precursor infrastructure for Cluster 2 capture-event #1 (first AI-designed drug approval). Does NOT yet cross P4 "regulator names AI-designed drugs as a distinct approval class" — the pilot addresses AI as a method within trials, not AI-designed molecules as an approval class. However, this is a Cluster 5 state-stamp firming event missed in prior cycles. Analyst-tier reports (intuitionlabs.ai) claim 10 named sponsor applicants (Insilico, Recursion/Exscientia, Schrödinger/Nimbus, Relay, BenevolentAI, Isomorphic, Iambic, Atomwise, Generate, AbCellera) with "public announcement of final cohort participants in August 2026" — the Federal Register primary does NOT name sponsors; analyst-tier sponsor list is HELD for independent primary byte-check. Urgency: Alert Cross-tie: sovereign-events-scout (US regulatory pilot structure); frame-contest-tracker (frame #4 — "Regulator will bless AI drugs" — this pilot does NOT cross that threshold, do not promote).

[CLUSTER 3 — BIG-PHARMA AI ADOPTION] — pre-seed baseline gap

Signal: Chai Discovery pharma-deal cluster — Chai-3 AI model rolled out to pharmaceutical partners since early 2026 with named adopters Bristol Myers Squibb (collaboration 2026-08-20), Novartis (collaboration 2026-07-13), Eli Lilly, Pfizer, argenx. Chai Discovery raised $400M Series C at $3.8B valuation. Primary URLs:

SILENCE ESCALATION

[CLUSTER 2 — AI-BIOTECH CLINICAL]

Signal: Isomorphic Labs — 7th consecutive cycle silence. No new press since 2026-07-16 ("Our approach to bioresilience"). No IND submission announcement, no first-patient-dose news, no site-initiation press, no clinical partner disclosure. Hassabis Davos end-2026 first-patient-dose commit now within the final calendar quarter (Oct-Dec 2026) with zero preparatory signal. Primary URL: https://www.isomorphiclabs.com/ (homepage; most-recent articles still dated 2026-02-18 as of 2026-10-02 fetch) Confirmation tier: OFFICIAL (absence of signal) Type: silence Consequence class: pipeline-progression (negative — commit vs. absence of preparatory evidence) Contradicts_baseline: potentially — if Hassabis commit was credible, preparatory press (IND filing, site initiation, DMC appointment) would typically precede first-patient dosing by weeks-to-months Convergence_tag: AI_drug_reaches_patient (negative evidence) Why it matters: Per Cycle 7 escalation rule ("elevate silence signal to Alert tier next cycle if 7th cycle silence continues"), THIS CYCLE escalates Isomorphic's clinical-dose silence to Alert tier. The structural question is binary: either (a) Isomorphic dose a patient by Dec 31, 2026 with minimal preparatory press (unusual in BigPharma clinical operations, possible given Isomorphic's secretive stance) or (b) Isomorphic misses the Hassabis commit. Both outcomes are informative — the first validates the AI-biotech-can-run-dark operating model, the second would be a credibility pullback for the AI-biotech sector's category-repricing narrative. Watch Q4 2026 for either confirmation path. Urgency: Alert Cross-tie: frame-contest-tracker (hook #3 — "Anthropic is the leader" / company-of-the-moment frame; Isomorphic's silence is counter-evidence for Google DeepMind/Isomorphic leading Cluster 2 if the commit misses).

HELD-FOR-PRIMARY LIST (carried forward — 32 + 3 added = 35; 0 resolved this cycle)

Prior 32 carried unchanged.

Additions this cycle (3):

Resolved this cycle: 0.

Prior-cycle special status:

CLUSTER STATE AT CLOSE

CAPTURE-EVENT FOUR-PART TEST AT CLOSE

  1. Closed-loop wet-lab primitive shipping at production scale — not_crossed (unchanged; no new in-window autonomous-lab closure demo).
  2. AI-designed drug reaches patients at scale (Phase 3 positive endpoint OR approval) — not_crossed (unchanged; Insilico Phase 3 dosing continues, no readout; Isomorphic silence 7th cycle).
  3. $2.75B benchmark met or exceeded by additional big-pharma deal — not_crossed (unchanged; Profluent-BioMarin deal structure not disclosed; even if it were disclosed and material, no public figure yet exceeds).
  4. Sovereign / regulatory framing crystallizes — partial (unchanged narrative — UK Sovereign AI Fund in Isomorphic + Huawei tie-ups + NMPA "AI + drug regulation" implementation opinions + Anthropic × US DOE Genesis Mission + (NEW baseline-gap) FDA Early-Phase AI Pilot Program; still does NOT cross the "regulator names AI-designed drugs as a distinct approval class" threshold).

Overall: Four-part test unchanged (P1/P2/P3 not_crossed, P4 partial). No capture-event upgrade this cycle. Underlying infrastructure is thickening around every part: scientific-agent layer (Cluster 1 Opus 5.5 + LSVP + Chai Discovery), big-pharma deal market (Cluster 3 Profluent-BioMarin), regulatory sandbox (Cluster 5 FDA Early-Phase AI Pilot). All firming, none crossing.

CROSS-TRACKER ROUTING

SILENCE-CLUSTERS NAMED (explicit silence IS signal)

COUNTS

RECENCY-STAMP COMPLIANCE

Pass. All in-window signal blocks carry primary URL and byte-verified date (where primary resolved). Four flagged items (Opus 5.5 anthropic.com direct URL 404; Rakovina-Celvion primary press URL unresolved — biospace index + Rakovina news-listing confirm existence; Sanofi-Regeneron deal-terms byte-check pending; FDA pilot sponsor list analyst-tier) are marked HELD for next cycle. Four baseline-gap items (Opus 5.5, LSVP, Chai Discovery cluster, FDA Early-Phase AI Pilot) are explicitly marked pre-seed / baseline-gap and routed to terminal-Scout fold proposal below.

Tue 2026-10-06 12:00 UTC (Tue+Fri cadence maintained). One Cluster 3 in-window Alert (Profluent-BioMarin) + three baseline-gap Alerts (Opus 5.5, LSVP, FDA Pilot) + Isomorphic silence escalation to Alert tier → four in-window Alert equivalents, but no capture-event part crosses → do NOT escalate to daily off-cycle. Watch items:

  1. Isomorphic Labs press page — any pre-dose preparatory signal (IND, site initiation, DMC appointment, clinical partner disclosure) before Q4 2026 end
  2. Chinese primary — MANDATORY to close this cycle's 2nd-consecutive zh gap; targets include cac.gov.cn, NMPA, StoneWise, Huawei/BGI/Baidu/ByteDance, XtalPi zh-side
  3. Profluent + BioMarin deal structure — SEC filing or follow-on disclosure byte-check
  4. anthropic.com/news/claude-opus-5-5 — canonical URL resolution + byte-check of biology benchmark numbers
  5. FDA FDA-2026-N-4390 docket — any sponsor-cohort announcement; also any CDER AI in drug development page updates
  6. Rakovina-Celvion primary URL — Rakovina press page direct URL
  7. Insilico GENESIS-IPF-3 Phase 3 — any safety / interim update

PROPAGATION GATE CHECK

  1. Alert-tier signals satisfy three-part stamp (URL resolves, byte-matched quote, page-date ≤ window end):
    • Profluent-BioMarin: ✅ (URL, date; terms not disclosed, flagged held)
    • Opus 5.5: ⚠️ URL via mobihealthnews republish only; anthropic.com canonical pending
    • LSVP: ✅ (support.claude.com + claude.com/form both resolve; launch date "earlier in September 2026" via mobihealthnews, LSVP page itself does not date-stamp)
    • FDA Pilot: ✅ (Federal Register PDF date confirmed 2026-04-29; sponsor list is analyst-tier, flagged held)
    • Chai Discovery cluster: ✅ (BMS Aug 20 + Novartis Jul 13 both have primary chaidiscovery.com URLs)
    • Isomorphic silence: ✅ (negative-signal: isomorphiclabs.com homepage shows no post past 2026-07-16 as of 2026-10-02)
  2. No quoted text without byte-match or [paraphrase] tag: ✅
  3. No out-of-window dates without context anchor: ✅ (baseline-gap items explicitly marked pre-seed / out-of-window)
  4. Counter-trend search performed each cluster (null acceptable; omission not): ✅ (silence clusters named for all 6)
  5. Cross-cluster and convergence-tag checks pass or flagged: ✅
  6. Held-for-primary list carried forward completely: ✅ (32 → 35; 0 resolved)
  7. Cross-tracker routing checked: ✅ (model-intelligence x2; sovereign-events-scout x2; frame-contest-tracker x1)
  8. Cluster state upgrade satisfies specific Alert-trigger evidence: ✅ (no state-stamp advance beyond "firming" language)
  9. Capture-event four-part test at close, each part named: ✅ (P1/P2/P3 not_crossed, P4 partial)

Internal stamp clears scan for baseline patch consideration.

PATCH PROPOSAL — for terminal-Scout to fold into .tracker_state/ai_biomedical_convergence_state.json

Cluster 1 baseline additions (pre-seed baseline gaps surfaced this cycle):

- Anthropic Claude Opus 5.5 release (2026-09-23, primary pending anthropic.com direct byte-check; interim: mobihealthnews.com/news/anthropic-launches-claude-opus-55-expanded-biology-capabilities) — long-horizon molecular prediction & design evaluation in collaboration with Dyno Therapeutics; expert evaluators rated "scientific novelty as comparable to the strongest model previously evaluated"; 40% lower cost than Opus 5, 30% faster output; available via AWS/GCP/Azure as "claude-opus-5-5". [Cycle-8 Cowork sweep 2026-10-02 — ADD, late-catch Cycle 6/7]
- Anthropic Life Sciences Verification Program (LSVP) launched beta ~2026-09-17 (primary: support.claude.com/en/articles/16975617 + claude.com/form/life-sciences-verification-program) — verified-access program for pharma companies, academic labs, biotech startups; access to Opus 5.5/Mythos 5.1/Opus 5/Sonnet 5; biology safeguards; credential + security + ethical review; Enterprise/Team/API only; up to 100 seats; optional High-risk Use add-on. [Cycle-8 Cowork sweep 2026-10-02 — ADD, late-catch Cycle 4/5/6/7]
- Chai Discovery / Chai-3 molecular foundation model + pharma adoption cluster — Novartis collaboration 2026-07-13 (primary: chaidiscovery.com/news/novartis-partnership); Bristol Myers Squibb collaboration 2026-08-20 (primary: chaidiscovery.com/news/bms-partnership); named additional adopters Eli Lilly, Pfizer, argenx; $400M Series C at $3.8B valuation. First specialist molecular-interaction foundation model vendor with multi-big-pharma adoption. [Cycle-8 Cowork sweep 2026-10-02 — ADD, late-catch Cycles 1-7]

Cluster 3 baseline additions (in-window):

- Profluent + BioMarin (2026-09-30, primary: profluent.bio/media/profluent-partners-with-biomarin-to-design-novel-medicines-using-ai) — AI protein design × enzyme replacement therapy for genetically defined conditions; deal structure not disclosed. Profluent's 2nd big-pharma deal (after $2.25B Lilly 2026-04-28). First AI-protein-design × ERT-modality big-pharma pairing. AI-designed per primary. [Cycle-8 Cowork sweep 2026-10-02 — ADD]

Cluster 3 documentation-only (non-AI per primary / sub-threshold counterparty):

- Rakovina Therapeutics + Celvion Therapeutics (2026-10-01, primary pending direct URL resolution; Rakovina news-listing confirms headline) — AI + RWD × precision oncology drug development; small-cap AI biotech × private biotech, NOT big-pharma counterparty; does NOT satisfy Cluster 3 big-pharma criterion. [Cycle-8 Cowork sweep 2026-10-02 — DOCUMENT ONLY; watch for recurrence of inter-AI-biotech contracting pattern]
- Sanofi + Regeneron immunology next-generation long-acting antibodies expansion (2026-10-01, primary pending Sanofi/Regeneron investor-page byte-check) — long-standing Dupixent-lineage partnership expansion; AI methodology NOT named in available primary; does NOT clear hook #7 gate. [Cycle-8 Cowork sweep 2026-10-02 — DOCUMENT ONLY; frame-contest-tracker 7-day watch for aggregator mis-tagging]
- Ro + Novo Nordisk Wegovy pill RWE collaboration (2026-09-30, primary pending byte-check) — real-world evidence partnership; NOT AI drug discovery. [Cycle-8 Cowork sweep 2026-10-02 — DOCUMENT ONLY]

Cluster 5 baseline additions (pre-seed baseline gap surfaced this cycle):

- FDA AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program (2026-04-29 Federal Register, Docket FDA-2026-N-4390, primary: public-inspection.federalregister.gov/2026-08281.pdf) — voluntary pilot for sponsors; scope: AI patient recruitment, dose escalation, safety monitoring, adaptive trial design, Phase-1-to-Phase-2 decision acceleration, biomarker assessment; comment deadline 2026-05-29; NIST AI RMF applied. Does NOT yet establish an AI-designed-drug approval class (hook #4 preservation). Analyst-tier sponsor list (10 companies) HELD for independent primary byte-check. [Cycle-8 Cowork sweep 2026-10-02 — ADD, baseline gap]

Held-for-primary additions (3):

- Profluent + BioMarin deal structure byte-check (upfront, milestones, royalties, equity — not disclosed in available primary)
- anthropic.com/news/claude-opus-5-5 canonical URL byte-check (mobihealthnews republish is OFFICIAL-tier; direct anthropic.com page returned 404)
- FDA Early-Phase AI Pilot sponsor cohort primary byte-check (10-sponsor list is analyst-tier; need FDA primary confirmation of August 2026 cohort announcement)

Alert-tier silence escalation (1):

- Isomorphic Labs — 7-cycle silence escalated to Alert tier per Cycle 7 escalation rule. No preparatory press for Hassabis Davos end-2026 first-patient commit as of 2026-10-02. Q4 2026 is final calendar window.

Baseline mutation is terminal-Scout's write per gotcha #6. Cowork produces this patch proposal; terminal folds confirmed items.

END SCAN_RESULT_AND_PATCH_PROPOSAL — Cycle 8, 2026-10-02.